Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Stracke Website

Mary L. Stracke, M.D.

Selected Publications

1)  Farina AR, Cappabianca L, Ruggeri P, Di Ianni N, Ragone M, Merolle S, Sano K, Stracke ML, Horowitz JM, Gulino A, Mackay AR.
Constitutive autotaxin transcription by Nmyc-amplified and non-amplified neuroblastoma cells is regulated by a novel AP-1 and SP-mediated mechanism and abrogated by curcumin.
FEBS Lett. 586: 3681-91, 2012.
2)  Azare J, Doane A, Leslie K, Chang Q, Berishaj M, Nnoli J, Mark K, Al-Ahmadie H, Gerald W, Hassimi M, Viale A, Stracke M, Lyden D, Bromberg J.
Stat3 mediates expression of autotaxin in breast cancer.
PLoS ONE. 6: e27851, 2011.
3)  Ptaszynska MM, Pendrak ML, Stracke ML, Roberts DD.
Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.
Mol. Cancer Res. 8: 309-21, 2010.
4)  Im E, Motiejunaite R, Aranda J, Park EY, Federico L, Kim TI, Clair T, Stracke ML, Smyth S, Kazlauskas A.
Phospholipase Cgamma activation drives increased production of autotaxin in endothelial cells and lysophosphatidic acid-dependent regression.
Mol. Cell. Biol. 30: 2401-10, 2010.
5)  Koh E, Bandle RW, Roberts DD, Stracke ML, Clair T.
Novel point mutations attenuate autotaxin activity.
Lipids Health Dis. 8: 4, 2009.
6)  Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD.
Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells.
Mol. Cancer Res. 6: 352-63, 2008.
7)  Zhao C, Fernandes MJ, Prestwich GD, Turgeon M, Di Battista J, Clair T, Poubelle PE, Bourgoin SG.
Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis?.
Mol. Pharmacol. 73: 587-600, 2008.
8)  Koh E, Clair T, Hermansen R, Bandle RW, Schiffmann E, Roberts DD, Stracke ML.
Sphingosine-1-phosphate initiates rapid retraction of pseudopodia by localized RhoA activation.
Cell. Signal. 19: 1328-38, 2007.
9)  Koh E, Bandle R, Clair T, Roberts DD, Stracke ML.
Trichostatin A and 5-aza-2'-deoxycytidine switch S1P from an inhibitor to a stimulator of motility through epigenetic regulation of S1P receptors.
Cancer Lett. 250: 53-62, 2007.
10)  Song J, Jie C, Polk P, Shridhar R, Clair T, Zhang J, Yin L, Keppler D.
The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin.
Biochem. Biophys. Res. Commun. 340: 175-82, 2006.
11)  Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC, Tan TH, Colburn NH.
Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion.
Mol. Cell. Biol. 26: 1297-306, 2006.
12)  Song J, Clair T, Noh JH, Eun JW, Ryu SY, Lee SN, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW.
Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate.
Biochem. Biophys. Res. Commun. 337: 967-75, 2005.
13)  Clair T, Koh E, Ptaszynska M, Bandle RW, Liotta LA, Schiffmann E, Stracke ML.
L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin.
Lipids Health Dis. 4: 5, 2005.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/16/2013.